OncoMatch/Clinical Trials/NCT06412497
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Is NCT06412497 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for severe aplastic anemia.
Treatment: Rituximab · Rabbit ATG · Cyclophosphamide · Fludarabine · Cell Infusion · Post-Transplant G-CSF · Tacrolimus · Mycophenolate Mofetil — A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: radiation therapy
Exception: unless not deemed excessive by radiation therapist for proposed low dose TBI exposure
Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify